In 2023, CanSino Biologics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, CanSino Biologics has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore CanSino Biologics’s data sources below and access millions more through our Disclosure Search.
In 2023, the total operational greenhouse gas (GHG) emissions of CanSino Biologics amounted to 37,294.91 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of CanSino Biologics increased by 22.21%, suggesting that the company faced challenges in reducing its emissions from its core operations. a b
In 2023, the total Scope 1 emissions of CanSino Biologics were 3,541.18 metric tons of CO₂ equivalent (tCO₂e). a
Since 2020, CanSino Biologics's Scope 1 emissions have decreased by 21.57%, reflecting a declining long-term trend in Scope 1 emissions over time. a b
Compared to the previous year (2022), CanSino Biologics's Scope 1 emissions decreased by 41.37%, highlighting the company's efforts to lower direct emissions from assets it owns or controls. a b
In 2023, CanSino Biologics reported Scope 2 greenhouse gas (GHG) emissions of 33,753.73 tCO₂e without specifying the calculation method. a
Since 2020, CanSino Biologics's Scope 2 greenhouse gas (GHG) emissions ( Unspecified Calculation Method) have increased by 163.18%, reflecting a rising long-term trend in Scope 2 emissions over time. a b
Compared to the previous year (2022), CanSino Biologics's Scope 2 emissions (Unspecified Calculation Method) rose by 37.9% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy a b
In 2023, CanSino Biologics reported its Scope 2 emissions using an unspecified methodology. a
In 2023, CanSino Biologics reported Scope 1 greenhouse gas (GHG) emissions of 3,541.18 tCO₂e and total revenues of USD 49 millions. This translates into an emissions intensity of 72.91 tCO₂e per millions USD. a
In 2023, CanSino Biologics reported a Scope 1 emissions intensity of 72.91 tCO₂e per millions USD. Compared to the peer group median of 23.6 , this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors. a
In 2023, CanSino Biologics ranked 22 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
This places CanSino Biologics among the least efficient performers, with one of the highest emissions intensities in its sector. a